Transaction · 0000905148-26-004065

Levin Michaela

Levin Michaela, CBO, reported a transaction classified as grant at Acrivon Therapeutics, Inc. involving 30000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 30000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACBO
ACRVAcrivon Therapeutics, Inc.
Filing timeSep 02
Trade dateAug 31, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$2.15
Pre-filing
1mo ago -30.2%1w ago +2.3%1d ago -4.2%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

ACRV price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ACRV since 2026-09-02Filed 2 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
grant
Code A
Identifier
0000905148-26-004065
Common Stock
Transaction date
Aug 31, 2026
Filed Sep 02, 2026, 08:30 PM · 2d delay
Shares
30.0k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
30.0k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Large Holdings Increase
-12score
Filing-only score

-12

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Business Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on September 1, 2027, su…

  2. F2

    Twenty-five percent (25%) of the shares subject to the option vest on September 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter,…

Original filing · 0000905148-26-004065
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ACRV